During Wednesday’s Current trade, Shares of Duke Energy Corp (NYSE:DUK), gain 0.66% to $72.90.
Duke Energy Florida owns coal-fired and natural gas generation providing about 9,000 megawatts of owned electric capacity to about 1.7 million customers in a 13,000-square-mile service area.
With its Florida regional headquarters located in St. Petersburg, Fla., Duke Energy is the largest electric power holding company in the United States with about $120 billion in total assets.
A sweltering hot Florida summer can cause your electric bill to jump as your air conditioning battles high humidity and temperatures comprising north of 90 degrees. But, you can survive the heat and your summer energy bills by following these simple tips from Duke Energy Florida.
Try these money-saving tips to assist reduce your electric use and save as the temperature rises:
- Set your thermostat to the highest comfortable setting. Energy used to cool a home during summer can account for half of a monthly electric bill. Adjusting your thermostat to 76 degrees from 73 degrees saves more than 15 percent in electricity costs. When leaving for the day, turn the setting up a few degrees.
- Keep the AC fan switch set to “auto” and save up to $25 a month as compared to leaving it set to “on” continuously as many people do.
- Change your air filters regularly. A dirty air filter can make a cooling system work harder, which uses more energy.
- Close blinds, drapes and shades during the hottest part of the day to keep the sun’s rays from heating the inside of your home.
- Turn off unnecessary lights, and use energy-efficient light bulbs that use less electricity and emit less heat.
Duke Energy Corporation, together with its auxiliaries, operates as an energy company in the United States and Latin America. It operates through three segments: Regulated Utilities, International Energy, and Commercial Power. The Regulated Utilities segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, Ohio, Kentucky, and Indiana; and transports and sells natural gas in southwestern Ohio and northern Kentucky.
Shares of Danaher Corporation (NYSE:DHR), declined -0.08% to $87.72, during its current trading session.
Danaher Corporation (DHR) declared that its wholly-owned partner, DH Europe Finance S.A. (“Danaher International”), has priced an offering of:
€500 million principal amount of floating rate senior notes due 2017 at an offering price of 100.000% of the principal amount;
€600 million principal amount of 1.000% senior notes due 2019 at an offering price of 99.696% of the principal amount;
€800 million principal amount of 1.700% senior notes due 2022 at an offering price of 99.651% of the principal amount; and
€800 million principal amount of 2.500% senior notes due 2025 at an offering price of 99.878% of the principal amount.
Danaher anticipates to receive net proceeds, after estimated expenses and the underwriters’ discounts and commissions, of about €2.68 billion. Danaher anticipates using the net proceeds from the offering to pay a portion of the purchase price of the formerly declared acquisition of Pall Corporation and for general corporate purposes. The senior notes will be fully and unconditionally guaranteed on a senior unsecured basis by Danaher.
Deutsche Bank AG, London Branch, Merrill Lynch International, BNP Paribas, HSBC Securities (USA) Inc. and Morgan Stanley & Co. International plc are acting as joint book-running managers for the offering.
The offering is being made following an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.
The offering of senior notes may be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement regarding the securities can be obtained from Deutsche Bank AG, London Branch at Winchester House, 1 Great Winchester Street, London EC2N 2DB, United Kingdom, Attention: GRS, Facsimile: +44 207 545 4455; and from Merrill Lynch International at 2 King Edward Street, London EC1A 1HQ, United Kingdom, Attention: Syndicate Desk, Facsimile +44 207 995 0048.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company’s Test & Measurement segment provides test, measurement, and monitoring products that are used in electronic design, manufacturing, and technology development; hardware and software solutions to deploy, manage, and secure communication network technologies and services; and tools, toolboxes, and automotive maintenance equipment. Its Environmental segment offers instrumentation and disinfection systems to analyze and manage the quality of water; and solutions and services focused on fuel dispensing, remote fuel administration, point-of-sale systems, payment systems, environmental compliance, vehicle tracking, and fleet administration.
Sanofi SA (ADR) (NYSE:SNY), during its Wednesday’s current trading session shares showed no change to $52.99.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Finally, PepsiCo, Inc. (NYSE:PEP), gained 0.35%, to $97.29.
The Board of Directors of PepsiCo, Inc. (PEP) declared a quarterly dividend of $0.7025 per share of PepsiCo common stock, a 7.3 percent enhance as compared to the comparable year-earlier period. The dividend is payable on September 30, 2015 to shareholders of record as of September 4, 2015. PepsiCo has paid successive quarterly cash dividends since 1965, and 2015 marks the company’s 43rd successive annual dividend enhance.
PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lay’s potato chips, Doritos tortilla chips, Cheetos cheese-flavored snacks, Tostitos tortilla chips, branded dips, Ruffles potato chips, Fritos corn chips, and Santitas tortilla chips.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
